Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung14
jRCT2031240580Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2025
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Osimertinib in combination with datopotamab deruxtecan with Osimertinib monotherapy (2 arms). Primary endpoint: Progression-free survival by blinded independent central review. Started Jan 2025; status: recruiting.
02
Drugs
osimertinibdatopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031240580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240580.